Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase NA 4Phase 1/2 3Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Melanoma 55Skin Neoplasms 16Carcinoma, Basal Cell 11Breast Neoplasms 10Sarcoma 8Lymphoma, T-Cell, Cutaneous 6Lung Neoplasms 5Keratosis, Actinic 5Carcinoma, Renal Cell 5Squamous Cell Carcinoma of Head and Neck 4Lymphoma 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Uveal Melanoma 3Sezary Syndrome 3Mycosis Fungoides 3Kidney Neoplasms 3Intraocular Lymphoma 3Hodgkin Disease 3Gastrointestinal Neoplasms 3Colonic Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Hepatocellular 3Breast Neoplasms, Male 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Urogenital Neoplasms × Dermatologic × Clear all
NCT07389525 2026-04-24

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Indiana University

Phase EARLY_PHASE1 Not yet recruiting
80 enrolled
DermatologicGastrointestinalSarcoma

Gastrointestinal Neoplasms, Melanoma, Sarcoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡